US FDA Suggests ‘Enhancements’ To Opioid Blueprint; CE Providers Want ‘Flexibility’
Executive Summary
The US FDA has some ideas for short-term improvements in the continuing education “blueprint” used as part of the opioid class REMS. Providers want more dramatic changes to the CE model itself.